MERLIN THERAPEUTICS INC
Last verified 2026-05-07. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $1.3Mattributed |
|---|---|
| Latest round | grant, $1.3M, 2025-01-01attributed |
| Founded | unknown |
| Headquarters | king of prussia, pa, usa |
| Industry | unknown |
| Stage | unknown |
| Website | merlintherapeutics.com |
Merlin Therapeutics develops therapies targeting genetic defects in neurofibromatosis type 2 (NF2), a rare disorder driving benign nervous-system tumours. It works toward treatments for NF2 patients across the disease's lifecycle. The company frames its mission as pursuing every viable therapeutic angle for the disorder.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-01-01 | grant | $1.3M | undisclosed |
Detected tech stack
Nginx, Jetpack, jQuery Migrate, web-vitals, WordPress, WordPress Block Editor, WordPress.com, PHP, MySQL, jquery 3.7.1
Provenance
| Fact | Status | Basis |
|---|---|---|
| Grant, $1.3M | attributed | sbir named as publisher. No document URL on file. |
| Total raised $1.3M | attributed | sbir named as publisher. No document URL on file. |
| Company existence | self-reported | merlintherapeutics.com, read 2026-05-07 |
| Description | self-reported | merlintherapeutics.com, read 2026-05-07 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.